Analysts fell to the sidelines weighing in on Edwards Lifesciences (EW – Research Report) and SAGE Therapeutics (SAGE – Research Report) with ...

Sage Therapeutics Inc. pushed off questions about potential mergers or acquisitions during its first earnings call since ...

Reports Q4 revenue $12.8M, consensus $14.4M. “We are proud to have helped thousands of women with postpartum depression in 2024. ZURZUVAE is ...

Spencer Rascoff, who has served as a member of Match Group's board since March 2024, succeeds Bernard Kim, who's stepping ...

Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...

Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...

Focus on executing Phase 3 safety study for lead candidate oral weekly risperidone (LYN-005) following positive data demonstrating efficacy compared to daily Risperdal Lyndra Therapeutics®, a ...

January 28, 2025--(BUSINESS WIRE)--Lyndra Therapeutics ®, a clinical-stage biopharmaceutical ... Under the leadership of outgoing President and CEO Jessica Ballinger, Lyndra completed the pivotal ...

Biogen Inc. is fending off a lawsuit in the Delaware Chancery Court over its recent offer to buy out Sage Therapeutics, its collaborator on a postpartum depression drug.

January 27, 2025--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) ("Sage" or "the Company"), today announced that its Board of Directors has initiated a process to explore strategic ...